Introduction
============

Cancer is no longer considered as a purely cell-intrinsic disease, for several reasons. First, it has become clear that the development of both solid and hematological neoplasms critically relies upon an intimate crosstalk with non-malignant components of the tumor microenvironment, including endothelial, stromal, as well as immune cells.[@R1]^-^[@R3] Second, the notion that cancer would constitute a self entity and hence go completely unnoticed by the immune system has now been abandoned.[@R4]^-^[@R6] Research over the past two decades has indeed demonstrated that the immune system not only interacts with (and attempts to control) developing neoplasms,[@R4] but also (1) removes damaged and stressed cells, which are generally more prone to become malignant than their healthy counterparts (a process known as anticancer immunosurveillance);[@R7]^,^[@R8] and (2) plays a critical role in the response of various malignancies to therapy.[@R9]^-^[@R11] Both these facets of the complex interaction between (pre)neoplastic and non-malignant compartments of the tumor microenvironment have rapidly attracted interest as potential targets for the development of novel anticancer therapies, and some of these strategies have already entered the clinical practice.[@R2]^,^[@R12]^-^[@R14] For instance, the monoclonal antibody bevacizumab, which is currently employed in patients with colorectal, lung, and renal carcinoma,[@R15]^,^[@R16] is specific for the vascular endothelial growth factor (VEGF), hence operating as an inhibitor of angiogenesis.[@R17]^,^[@R18] Along similar lines, ipilimumab, which has been approved by the US Food and Drug Administration (FDA) for use in patients with unresectable or metastatic melanoma in 2011,[@R19]^-^[@R21] inhibits the immunosuppressive receptor cytotoxic T lymphocyte-associated protein 4 (CTLA4), thereby exerting robust immunostimulatory effects.[@R22]^,^[@R23]

Importantly, besides mediating the antineoplastic effects of a variety of active and passive immunotherapeutic interventions,[@R24]^,^[@R25] the immune system appears to play a critical role in the response of several tumors to conventional therapeutic regimens as well as to targeted anticancer agents.[@R10]^,^[@R11] In support of this notion, high levels of tumor-infiltrating CD8^+^ T cells, alone or combined with limited amounts of intratumoral CD4^+^CD25^+^FOXP3^+^ regulatory T cells (Tregs), have been associated with improved disease outcome upon therapy in patients affected by a variety of solid neoplasms, including (but not limited to) breast carcinoma.[@R8]^,^[@R26]^,^[@R27] In addition, an ever increasing amount of preclinical data indicates that the efficacy of various anticancer agents and several forms of radiotherapy depends, at least in part, on an intact immune system.[@R28]^-^[@R32]

Schematically, anticancer chemotherapeutics (as well as radiotherapy) can activate tumor-targeting immune responses that potentially eradicate the residual (chemo- or radioresistant) disease, hence leading to long-term clinical remissions, via 4, non-mutually exclusive mechanisms: (1) by directly stimulating the effector functions of innate or adaptive immune cells; (2) by inhibiting the immunosuppressive circuitries set in place by malignant cells to allow for tumor progression; (3) by enhancing the antigenicity of living cancer cells, their immunogenicity, or their susceptibility to immune effector mechanisms; or (4) by stimulating a peculiar type of apoptosis that results in the elicitation of adaptive immune responses against dead cell-associated antigens.[@R10]^,^[@R11]^,^[@R33]^-^[@R36] The cellular and molecular circuitries involved in the capacity of selected chemotherapeutics to directly modulate the activity of immune cells and/or to increase the antigenicity of neoplastic cells, their immunogenicity or propensity to succumb to immune effectors have been reviewed elsewhere.[@R10]^,^[@R11]^,^[@R34]

Immunogenic cell death (ICD) obligatorily relies on the emission of a spatiotemporally defined combination of signals by dying cells.[@R35]^-^[@R39] Such damage-associated molecular patterns (DAMPs) include (but presumably are not limited to): (1) the pre-apoptotic exposure of the endoplasmic reticulum chaperone calreticulin (CRT) to the outer leaflet of the plasma membrane; (2) the active secretion of ATP, which mainly occurs in the blebbing phase of the apoptotic program; and (3) the post-mortem release of the non-histone chromatin-binding protein high mobility group box 1 (HMGB1).[@R35]^,^[@R36]^,^[@R40] Altogether and in the correct order, these signals promote the uptake of apoptotic corpses by antigen-presenting cells including dendritic cells (DCs), the processing and presentation of dead cell-associated antigens, and the elicitation of an adaptive, interleukin (IL)-1β-, IL-17-, and interferon γ (IFNγ)-dependent immune response against such antigens.[@R35]^,^[@R36]^,^[@R40] A precise description of the molecular and cellular mechanisms that underlie the immunogenicity of cell death largely exceed the scope of this Trial Watch and can be found elsewhere.[@R35]^,^[@R36]^,^[@R40]

Importantly, although measuring CRT exposure, ATP secretion, and HMGB1 release can be useful to identify ICD-inducing agents,[@R41]^,^[@R42] vaccination experiments constitute the gold standard approach to characterize immunogenic instances of cell death.[@R33]^,^[@R36] In this setting, immunocompetent mice are vaccinated with syngeneic cancer cells that are dying in response to a putative ICD inducer, and---one week later---challenged with living cancer cells of the same type. If a majority of these mice does not develop tumors, the malignant cells injected as a vaccine were indeed succumbing to ICD.[@R36] So far, only a few clinically relevant agents have been shown to trigger bona fide ICD.[@R43] These agents include (1) cyclophosphamide, an alkylating agent nowadays employed for the treatment of acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), breast carcinoma, chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), lymphoma, multiple myeloma (MM), mycosis fungoides, neuroblastoma, ovarian carcinoma, and retinoblastoma;[@R44] (2) doxorubicin, an anthracycline currently approved by the FDA for use in patients with ALL, AML, breast carcinoma, gastric cancer, lymphoma, MM, neuroblastoma, ovarian carcinoma, small cell lung carcinoma (SCLC), soft tissue and bone sarcomas, thyroid carcinoma, transitional cell bladder carcinoma, and Wilms' tumor;[@R45]^,^[@R46] (3) epirubicin, an anthracycline commonly employed for the treatment of breast carcinoma;[@R45]^,^[@R46] (4) idarubicin, an anthracycline licensed by the FDA for use in AML;[@R46]^,^[@R47] (5) mitoxantrone, an anthracenedione nowadays used in the clinic for the therapy of multiple sclerosis as well as acute leukemia, breast carcinoma, non-Hodgkin lymphoma (NHL), and prostate cancer;[@R45]^,^[@R46] (6) oxaliplatin, a platinum-containing drug licensed for use in combination with 5-fluorouracil and folinic acid in patients with advanced colorectal carcinoma;[@R48]^-^[@R50] and (7) patupilone (also known as epothilone B or EPO906) a microtubular inhibitor that has not yet been approved for use in humans.[@R8]^,^[@R51] Indeed, although clinically employed agents including various microtubular inhibitors other than epothilones (e.g., paclitaxel) and cardiac glycosides (e.g., digoxin, digitoxin) are very efficient at converting non-immunogenic instances of cell death into immunogenic ones, they are unable to trigger ICD as standalone interventions.[@R8]^,^[@R41]^,^[@R42]

Along the lines of our Trial Watch series,[@R52]^,^[@R53] here we discuss recent discoveries related to the use of ICD inducers in cancer patients, presenting high-impact studies that have been published during the last 13 mo. In addition, we summarize the clinical trials that have been initiated in the same period to assess the antineoplastic profile of these immunogenic drugs as off-label therapeutic interventions.

Update on Clinical Reports
==========================

As cyclophosphamide, doxorubicin, epirubicin, idarubicin, mitoxantrone, oxaliplatin, and patupilone are all approved by the FDA or other international regulatory agencies for the treatment of specific malignancies, the safety concerns related to the use of these molecules in cancer patients are limited.[@R54] This still translates into a huge number of clinical trials investigating the possibility that ICD inducers might exert robust antineoplastic effects as off-label therapeutic interventions. During the last 13 mo, the results of no less than 44 studies assessing the efficacy of ICD inducers in (partially or completely) off-label clinical settings have been published in peer-reviewed scientific journals (source <http://www.ncbi.nlm.nih.gov/pubmed>) ([Table 1](#T1){ref-type="table"}).

###### **Table 1.** Recently published clinical trials investigating the therapeutic profile of ICD inducers employed as off-label interventions.\*

  Drug                                          Indication(s)                                             Phase                                                         Note                                                     Ref.
  --------------------------------------------- --------------------------------------------------------- ------------------------------------------------------------- -------------------------------------------------------- --------
  Cyclophosphamide                              Colorectal carcinoma                                      I                                                             Combined with imatinib and bevacizumab                   [@R62]
  Melanoma                                      II/III                                                    Combined with low-dose IL-2                                   [@R56]                                                   
  NSCLC                                         III                                                       Combined with MUC1-specific vaccine                           [@R57]                                                   
  T-cell prolymphocytic leukemia                II                                                        Combined with fludarabine, mitoxantrone and alemtuzumab       [@R55]                                                   
  Solid tumors                                  I                                                         Combined with low-dose IL-2 and imatinib                      [@R58],[@R59]                                            
  Combined with sorafenib and bevacizumab       [@R60]                                                                                                                                                                           
  Ib                                            Combined with an IL-2-based immunocytokine                [@R61]                                                                                                                 
  Doxorubicin                                   Hepatocellular carcinoma                                  III                                                           As a single agent                                        [@R63]
  Osteosarcoma                                  II                                                        Combined with ifosfamide, cisplatin and methotrexate          [@R64]                                                   
  Prostate cancer                               II                                                        Combined with androgen-deprivation therapy and ketoconazole   [@R65]                                                   
  Urothelial tract cancer                       II                                                        Combined with ifosfamide, gemcitabine and cisplatin           [@R67]                                                   
  II                                            In its pegylated liposomal form                           [@R66]                                                                                                                 
  Solid tumors                                  I                                                         Combined with oxaliplatin                                     [@R68]                                                   
  Epirubicin                                    Gastresophageal carcinoma                                 I                                                             Combined with bortezomib, carboplatin and capecitabine   [@R70]
  III                                           Combined with oxaliplatin, capecitabine and panitumumab   [@R69]                                                                                                                 
  Transitional bladder carcinoma                II                                                        Combined with methotrexate, paclitaxel and carboplatin        [@R71]                                                   
  Oxaliplatin                                   Biliary tract and pancreatic carcinoma                    I                                                             Combined with sorafenib and capecitabine                 [@R92]
  Breast carcinoma                              II                                                        Combined with docetaxel                                       [@R75]                                                   
  II                                            Combined with capecitabine                                [@R74]                                                                                                                 
  Chronic lymphocytic leukemia                  I/II                                                      Combined with fludarabine, cytarabine and rituximab           [@R72]                                                   
  Gallbladder cancer                            II                                                        Combined with gemcitabine                                     [@R94]                                                   
  Gastric carcinoma Gastresophageal carcinoma   I                                                         Combined with docetaxel and vandetanib                        [@R90]                                                   
  I                                             Combined with docetaxel and capecitabine                  [@R88]                                                                                                                 
  I                                             Combined with sunitinib and capecitabine                  [@R86]                                                                                                                 
  I                                             Combined with S-1 and irinotecan                          [@R82]                                                                                                                 
  I/II                                          Combined with radiotherapy and docetaxel                  [@R84]                                                                                                                 
  I/II                                          Combined with docetaxel and capecitabine                  [@R81]                                                                                                                 
  II                                            Combined with capecitabine and bevacizumab                [@R80]                                                                                                                 
  II                                            Combined with docetaxel                                   [@R87]                                                                                                                 
  II                                            Combined with docetaxel and capecitabine                  [@R89]                                                                                                                 
  II                                            Combined with docetaxel and S-1                           [@R83]                                                                                                                 
  II                                            Combined with S-1                                         [@R79]                                                                                                                 
  II                                            Combined with sorafenib                                   [@R85]                                                                                                                 
  Germ cell tumors                              II                                                        Combined with bevacizumab                                     [@R73]                                                   
  Nasopharyngeal carcinoma                      III                                                       Combined with radiotherapy                                    [@R78]                                                   
  NSCLC                                         II                                                        Combined with docetaxel                                       [@R77]                                                   
  II                                            Combined docetaxel and bevacizumab                        [@R76]                                                                                                                 
  Ovarian carcinoma                             II                                                        Combined with gemcitabine                                     [@R95]                                                   
  II                                            Combined with topotecan                                   [@R96]                                                                                                                 
  Pancreatic carcinoma                          I                                                         Combined with gemcitabine, erlotinib and radiation therapy    [@R91]                                                   
  II                                            Combined with gemcitabine and radiation therapy           [@R93]                                                                                                                 
  Transitional bladder carcinoma                II                                                        Combined with gemcitabine                                     [@R97]                                                   
  Solid tumors                                  I                                                         Combined with docetaxel                                       [@R98]                                                   
  II                                            Combined with gemcitabine                                 [@R99]                                                                                                                 

**Abbreviations:** ICD, immunogenic cell death; IL-2, interleukin-2; MUC1, mucin 1; NSCLC, non-small cell lung carcinoma. \*between 2012, December 1st and the day of submission.

In particular, cyclophosphamide has been tested as a possible alternative to standard therapeutic approaches in patients affected by (1) T-cell promyelocytic leukemia, as part of an induction chemotherapeutic cocktail including fludarabine and mitoxantrone;[@R55] (2) melanoma, according to a metronomic schedule in combination with low-dose IL-2;[@R56] (3) non-small cell lung carcinoma (NSCLC), as part of a therapeutic regimen encompassing a mucin 1-targeting vaccine;[@R57] or (4) various solid tumors, including colorectal carcinoma, in combination with low-dose IL-2 and/or tyrosine kinase receptor inhibitors such as sorafenib and imatinib.[@R58]^-^[@R62] Altogether, the results of these studies suggest that metronomic cyclophosphamide can be safely combined with conventional chemotherapeutic as well as with targeted anticancer agents and often results in immunological responses that may be therapeutically significant, at least in some patients.

The possibility that doxorubicin might promote therapeutic responses in off-label clinical settings has recently been investigated in individuals with (1) hepatocellular carcinoma (HCC), as a standalone palliative regimen compared with 5-fluorouracil, folinic acid, and oxaliplatin;[@R63] (2) non-metastatic osteosarcoma, in combination with cisplatin high-dose ifosfamide (an alkylating mustard with a broad antineoplastic activity), cisplatin, and high-dose methotrexate;[@R64] (3) advanced prostate cancer, in the context of androgen deprivation therapy;[@R65] (4) tumors of the urothelial tract, either in its pegylated form as a single agent or combined with cisplatin, ifosfamide, and gemcitabine (a nucleoside analog licensed for the treatment of pancreatic cancer, NSCLC, breast carcinoma, and ovarian cancer);[@R66]^,^[@R67] as well as (5) in pediatric patients affected by relapsed or refractory extracranial non-hematopoietic solid tumors, in the context of oxaliplatin-based chemotherapy.[@R68] Conversely, epirubicin has been investigated as a potential alternative to standard therapeutic protocols in subjects bearing (1) advanced gastresophageal tumors, in combination with conventional cytotoxic agents and/or panitumumab, an FDA-approved monoclonal antibody specific for the epidermal growth factor receptor (EGFR);[@R69]^,^[@R70] or (2) transitional bladder carcinoma, as a second-line intervention for individuals who failed cisplatin- and gemcitabine-based first-line chemotherapy.[@R71] These anthracycline-based chemotherapeutic cocktails were generally well tolerated, but often failed to ameliorate disease outcome as compared with gold-standard therapeutic interventions.

During the last 13 mo, the clinical profile of oxaliplatin as an off label therapeutic intervention has been assessed in patients with (1) aggressive relapsed or refractory CLL, as part of a chemotherapeutic regimen involving fludarabine, cytarabine (a nucleoside analog approved for the treatment of various hematological malignancies), and rituximab (a CD20-targeting monoclonal antibody currently employed against CLL and NHL);[@R72] (2) refractory germ cell tumors, in combination with bevacizumab;[@R73] (3) breast carcinoma, combined with capecitabine (the precursor of 5-fluorouracil) or docetaxel (a microtubular inhibitor of the taxane family currently employed against various carcinomas);[@R74]^,^[@R75] (4) NSCLC, as part of a docetaxel-based chemotherapy;[@R76]^,^[@R77] (5) advanced nasopharyngeal carcinoma, coupled to radiation therapy;[@R78] (6) gastric or gastresophageal carcinoma, most frequently in the context of a chemotherapeutic cocktail involving docetaxel, capecitabine, or S-1 (an oral fluoropyrimidine currently approved for the treatment of gastric cancer);[@R79]^-^[@R90] (7) pancreatic, gallbladder, or biliary tract tumors, often in combination with gemcitabine-based chemotherapy;[@R91]^-^[@R94] (8) ovarian or bladder carcinoma, combined with conventional (often gemcitabine-based) therapeutic interventions;[@R95]^-^[@R97] or (9) various solid tumors, again in combination with cytotoxic chemotherapy.[@R98]^,^[@R99] Taken together, the results of these clinical trials, most of which were Phase I or II studies, indicate that oxaliplatin exerts promising antineoplastic effects in patients affected by several tumors other than colorectal carcinoma. Large, randomized Phase III trials will have to evaluate the true clinical profile of oxaliplatin in these settings.

During the last 13 mo, several publications have provided novel insights into the signaling pathways that underlie ICD and its translational relevance. For instance, we have dissected the molecular cascades whereby autophagy is responsible for the secretion of ATP in the course of ICD,[@R100]^,^[@R101] and demonstrated that both ATP and chemokine (C-C motif) ligand 2 (CCL2),[@R102]^-^[@R104] but not tumor necrosis factor α (TNFα),[@R105] are responsible for the therapeutically relevant accumulation of inflammatory DC-like cells within neoplastic lesions treated with ICD inducers. In addition, we and others have demonstrated a critical role for the gut microbiota in the therapeutic activity of cyclophosphamide and other immunostimulatory regimens.[@R106]^,^[@R107] The group headed by Patrizia Agostinis showed that in some circumstances autophagy may inhibit, rather than promote, ICD,[@R108] and that the signaling cascades elicited by hypericin-based photodynamic therapy (another bona fide ICD inducer) are amplified by selected members of the Bcl-2 protein family,[@R108] including phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1, best known as NOXA) but not BCL2-like 11 (BCL2L11, best known as BIM).[@R109] The reasons why in some cases autophagy is critically required for ICD while in others appears to inhibit it remain unclear, but may relate to differences in the experimental models employed. Indeed, also the molecular cascades that underlie the pre-apoptotic exposure of calreticulin in response to anthracycline and hypericin-based photodynamic therapy overlap to a large extent, but not entirely.[@R110] Of note, recent data ascribe to the circulating levels of various ICD-associated molecules, including HMGB1 and one of its receptors, advanced glycosylation end product-specific receptor (AGER, best known as RAGE), prognostic or predictive relevance in patients with breast, pancreatic, or colorectal carcinoma.[@R111]^-^[@R113] Additional studies are required to fully understand the prognostic or predictive potential of circulating ICD markers.

Update on Clinical Trials Testing Immunogenic Cell Death Inducers
=================================================================

When this Trial Watch was being redacted (December 2013), official sources listed no less than 255 clinical trials launched after 2012, December 1st to evaluate the therapeutic profile of bona fide ICD inducers in cancer patients (source <http://www.clinicaltrials.gov>). One hundred 53 of these studies (83 involving cyclophosphamide, 63 doxorubicin, 14 epirubicin, 6 idarubicin, 7 mitoxantrone, and 32 oxaliplatin) were performed in on-label clinical settings, and hence will not be further discussed here. In addition, during the last 13 mo, 107 clinical trials have been launched to assess the clinical activity of ICD inducers in off-label settings. Of these studies, 27 involve cyclophosphamide, 17 doxorubicin, 6 epirubicin, 7 idarubicin, and 53 oxaliplatin.

Cyclophosphamide is being tested as an off-label intervention (1) in melanoma patients, either as part of a fludarabine- and IL-2-containing, non-myeloablative conditioning regimen combined to the adoptive transfer of tumor-infiltrating lymphocytes[@R24]^,^[@R114] (NCT01807182; NCT01814046; NCT01883323; NCT01946373; NCT01955460; NCT01993719; NCT01995344), or given on a metronomic schedule in support of low-dose intravenous IL-2[@R58]^,^[@R59] (NCT01833767) or an allogeneic melanoma cell line engineered to express the immunostimulatory protein tumor necrosis factor (ligand) superfamily, member 9 (TNFSF9, best known as CD137L)[@R115] (NCT01898039); (2) in patients with various forms of sarcoma, combined with a vincristine-containing (radio)therapeutic regimen (NCT01864109; NCT01871766; NCT01946529); (3) in children affected by hematopoietic neoplasms, as part of a non-myeloablative conditioning regimen preceding allogeneic stem cell transplantation (ASCT) (NCT01824693), or solid tumors, in combination with other chemotherapeutics (NCT01858571; NCT01987596); (4) in medulloblastoma patients, as part of combinatorial induction or maintenance regimens (NCT01878617; NCT02017964); (5) in individuals with lung carcinoma, either at metronomic doses in support of conventional chemotherapy (NCT01947062) or in combination with a vaccine based on cancer cell-derived autophagosomes[@R116] (NCT01909752); and (6) in patients affected by a variety of other hematological and solid tumors, including Waldenström\'s macroglobulinemia (NCT01788020), glioblastoma (NCT01903330), esophageal carcinoma (NCT01795976), renal cell carcinoma (NCT01943188), endometrial carcinoma (NCT01918124), colorectal carcinoma (NCT01966289), and others (NCT01804634; NCT01967823) ([Table 2](#T2){ref-type="table"}).

###### **Table 2.** Clinical trials recently launched to assess the therapeutic profile of cyclophosphamide employed as off-label intervention.\*

  Indication(s)                                               Phase                                                       Status                                                                  Notes                                                                             Ref.
  ----------------------------------------------------------- ----------------------------------------------------------- ----------------------------------------------------------------------- --------------------------------------------------------------------------------- -------------
  Colorectal carcinoma                                        I                                                           Not yet recruiting                                                      Combined with a cancer cell-based vaccine and a DNA methyltransferase inhibitor   NCT01966289
  DSRCT                                                       II                                                          Recruiting                                                              Combined with vincristine-based chemotherapy and radiation therapy                NCT01946529
  Endometrial carcinoma                                       II                                                          Active, not recruiting                                                  Combined with cisplatin, doxorubicin and radiation therapy                        NCT01918124
  Esophageal cancer                                           II                                                          Not yet recruiting                                                      As part of non-myeloablative conditioning followed by ACT                         NCT01795976
  Ewing sarcoma                                               II                                                          Recruiting                                                              Combined with doxorubicin-based chemotherapy and radiation therapy                NCT01864109
  Glioblastoma                                                II                                                          Not yet recruiting                                                      Combined with bevacizumab, a cell-based vaccine and GM-CSF                        NCT01903330
  Lung carcinoma                                              II                                                          Recruiting                                                              Combined with an autophagosome-derived vaccine and GM-CSF or imiquimod            NCT01909752
  III                                                         Not yet recruiting                                          Combined with cisplatin and etoposide                                   NCT01947062                                                                       
  Medulloblastoma                                             II                                                          Not yet recruiting                                                      Combined with various conventional chemotherapeutics                              NCT02017964
  II                                                          Recruiting                                                  Combined with conventional chemotherapy upon craniospinal irradiation   NCT01878617                                                                       
  Melanoma                                                    I                                                           Not yet recruiting                                                      As part of non-myeloablative conditioning followed by ACT                         NCT01955460
  Recruiting                                                  As part of non-myeloablative conditioning followed by ACT   NCT01946373                                                                                                                                               
  I/II                                                        Recruiting                                                  Combined with various conventional chemotherapeutics upon irradiation   NCT01898039                                                                       
  II                                                          Not yet recruiting                                          Combined with an allogeneic cell-based vaccine expressing CD137L        NCT01883323                                                                       
  As part of non-myeloablative conditioning followed by ACT   NCT01995344                                                                                                                                                                                                           
  Recruiting                                                  As part of non-myeloablative conditioning followed by ACT   NCT01807182                                                                                                                                               
  NCT01814046                                                                                                                                                                                                                                                                       
  NCT01993719                                                                                                                                                                                                                                                                       
  Combined with IL-2                                          NCT01833767                                                                                                                                                                                                           
  Myelomonocytic leukemia                                     II                                                          Recruiting                                                              As part of non-myeloablative conditioning followed by ASCT                        NCT01824693
  Renal cell carcinoma                                        I                                                           Not yet recruiting                                                      As part of non-myeloablative conditioning preceded by SBRT and followed by ACT    NCT01943188
  Rhabdomyosarcoma                                            II                                                          Recruiting                                                              Combined with multimodal therapy                                                  NCT01871766
  Solid tumors                                                II                                                          Recruiting                                                              As part of non-myeloablative conditioning followed by haploidentical BMT          NCT01804634
  As part of non-myeloablative conditioning followed by ACT   NCT01967823                                                                                                                                                                                                           
  III                                                         Not yet recruiting                                          Combined with celecoxib, etoposide and thalidomide                      NCT01858571                                                                       
  Recruiting                                                  Combined with standard chemotherapy ± G-CSF                 NCT01987596                                                                                                                                               
  Waldenström\'s macroglobulinemia                            III                                                         Not yet recruiting                                                      Combined with rituximab, dexamethasone ± bortezomib                               NCT01788020

**Abbreviations:** ACT, adoptive cell transfer; ASCT, allogeneic stem cell transplantation; BMT, bone marrow transplantation; CD137L, CD137 ligand; DSRCT, desmoplastic small round cell tumor; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; IL-2, interleukin-2; SBRT; stereotactic body radiation therapy. \*between 2012, December 1st and the day of submission.

The safety and therapeutic profile of doxorubicin employed as an off-label intervention are currently under investigation (1) in patients with HCC or intrahepatic cholangiocellular carcinoma (ICC), most often in the context of transcatheter arterial chemoembolization (TACE) and/or combined with sorafenib[@R117]^,^[@R118] (NCT01798134; NCT01798147; NCT01798160; NCT01840592; NCT01857726; NCT01858207; NCT01906216; NCT01966133); (2) in women with reproductive tract neoplasms, either as a standalone therapeutic intervention, be it unconjugated (NCT01849874; NCT01767155) or in the form of AEZS-108 (i.e., conjugated to gonadotropin-releasing hormone 1)[@R119] (NCT01767155), either combined with conventional chemotherapeutics and/or radiotherapy (NCT01918124; NCT01970722), or co-administered with trabectedin, an orphan drug[@R120]^,^[@R121] (NCT01846611); and (3) in subjects affected by other malignancies, including retinoblastoma (NCT01783535), glioblastoma (NCT01851733), salivary gland cancer (NCT01969578), or multiple neoplasms (NCT01970540). In addition, epirubicin is being evaluated as an off-label therapeutic intervention against esophageal and gastric carcinomas, most often in combination with a platinum derivative[@R50] and 5-fluorouracil (or capecitabine)[@R122] (NCT01787539; NCT01870791; NCT01924819); MM, in combination with the proteasomal inhibitor bortezomib and dexamethasone[@R123] prior to ASCT (NCT01852799; NCT01868828); and HCC, in the context of TACE (NCT01833286). Finally, the off-label clinical potential of idarubicin is being assessed (1) in ALL patients, either as a standalone therapeutic intervention (NCT01990807), either combined with etoposide (a DNA-damaging chemical) in the context of ASCT conditioning (NCT01873807), or as part of a fludarabine- and cytarabine-containing chemotherapeutic cocktail (NCT02013167); (2) in subjects with acute promyelocytic leukemia, in combination with all-*trans* retinoic acid (NCT01987297); (3) in NHL patients, as a standalone therapeutic measure (NCT01958996); and (4) in individuals affected by myelodysplastic syndromes, combined with cytarabine-based chemotherapy (NCT01812252; NCT01831232) ([Table 3](#T3){ref-type="table"}).

###### **Table 3.** Clinical trials recently launched to assess the therapeutic profile of FDA-approved anthracyclines employed as off-label interventions.\*

  Drug                                                             Indication(s)                                                      Phase                                                                             Status                                                            Note                                                             Ref.
  ---------------------------------------------------------------- ------------------------------------------------------------------ --------------------------------------------------------------------------------- ----------------------------------------------------------------- ---------------------------------------------------------------- -------------
  Doxorubicin                                                      Glioblastoma                                                       n.a.                                                                              Not yet recruiting                                                Combined with magnetic resonance imaging-guided laser ablation   NCT01851733
  Hepatocellular carcinoma                                         n.a.                                                               Recruiting                                                                        In the context of DEB-based TACE                                  NCT01798134                                                      
  In the context of TACE, alone or combined with cisplatin         NCT01857726                                                                                                                                                                                                                                                                             
  II                                                               Recruiting                                                         Combined with sorafenib                                                           NCT01840592                                                                                                                        
  In the context of TACE, combined with RFA                        NCT01858207                                                                                                                                                                                                                                                                             
  II/III                                                           Recruiting                                                         In the context of TACE, combined with sorafenib                                   NCT01906216                                                                                                                        
  III                                                              Enrolling by invitation                                            In the context of TACE, combined with ethiodized oil                              NCT01966133                                                                                                                        
  IV                                                               Active, not recruiting                                             In the context of DEB-based TACE                                                  NCT01798160                                                                                                                        
  Intrahepatic cholangiocellular carcinoma                         IV                                                                 Recruiting                                                                        In the context of DEB-based TACE                                  NCT01798147                                                      
  Reproductive tract tumors                                        n.a.                                                               Not yet recruiting                                                                As PLD in combination with other chemotherapeutics                NCT01970722                                                      
  II                                                               Active, not recruiting                                             Combined with cyclophosphamide, cisplatin, and radiation therapy                  NCT01918124                                                                                                                        
  III                                                              Recruiting                                                         As single agent, unconjugated or conjugated to gonadotropin-releasing hormone 1   NCT01767155                                                                                                                        
  As single agent                                                  NCT01849874                                                                                                                                                                                                                                                                             
  As single agent or combined with dexamethasone and trabectedin   NCT01846611                                                                                                                                                                                                                                                                             
  Retinoblastoma                                                   II                                                                 Recruiting                                                                        Combined with conventional chemotherapy and plaque radiotherapy   NCT01783535                                                      
  Salivary gland cancer                                            II                                                                 Not yet recruiting                                                                Combined with cisplatin                                           NCT01969578                                                      
  Solid tumors                                                     I                                                                  Recruiting                                                                        Combined with lurbinectedin                                       NCT01970540                                                      
  Epirubicin                                                       Esophageal carcinoma Gastric carcinoma Gastresophageal carcinoma   II                                                                                Recruiting                                                        EOX regimen combined with intravenous omega-3 fish oil           NCT01870791
  II/III                                                           Recruiting                                                         Combined with 5-FU and cisplatin                                                  NCT01924819                                                                                                                        
  EOX regimen                                                      NCT01787539                                                                                                                                                                                                                                                                             
  Hepatocellular carcinoma                                         III                                                                Not yet recruiting                                                                In the context of TACE                                            NCT01833286                                                      
  Multiple myeloma                                                 II                                                                 Recruiting                                                                        Combined with bortezomib, dexamethasone and autologous SCT        NCT01852799                                                      
  IV                                                               Recruiting                                                         Combined with bortezomib, dexamethasone and autologous SCT                        NCT01868828                                                                                                                        
  Idarubicin                                                       ALL                                                                III                                                                               Not yet recruiting                                                Combined with standard of care chemotherapeutic agents           NCT02013167
  IV                                                               Recruiting                                                         As single agent                                                                   NCT01990807                                                                                                                        
  As part of intensified conditioning followed by autologous SCT   NCT01873807                                                                                                                                                                                                                                                                             
  AML MDS                                                          II                                                                 Recruiting                                                                        Combined with cytarabine and pravastatin                          NCT01831232                                                      
  APL                                                              IV                                                                 Recruiting                                                                        Combined with all-*trans* retinoic acid                           NCT01987297                                                      
  MDS                                                              n.a.                                                               Recruiting                                                                        Combined with cytarabine                                          NCT01812252                                                      
  NHL                                                              I/II                                                               Recruiting                                                                        As single agent                                                   NCT01958996                                                      

**Abbreviations:** 5-FU, 5-fluorouracil; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; APL, acute promyelocytic leukemia; DEB, drug-eluting bead; EOX, epirubicin + oxaliplatin + capecitabine; FDA, Food and Drug Administration; MDS, myelodysplastic syndrome; n.a., not available; NHL, non-Hodgkin\'s lymphoma; PLD, pegylated liposomal doxorubicin; RFA, radiofrequency ablation; SCT, stem cell transplantation; TACE, transcatheter arterial chemoembolization. \*between 2012, December 1st and the day of submission.

The safety and efficacy of oxaliplatin employed as an off-label therapeutic intervention are being assessed (1) in patients affected by gastric or esophageal carcinoma, most frequently in the context of the so-called DOX (docetaxel plus oxaliplatin plus capecitabine), EOX (epirubicin plus oxaliplatin plus capecitabine), FOLFOX (folinic acid plus 5-fluouracil plus oxaliplatin), SOX (S-1 plus oxaliplatin) or XELOX (capecitabine plus oxaliplatin) regimens (NCT01747551; NCT01748773; NCT01748851; NCT01757366; NCT01761461; NCT01769508; NCT01787539; NCT01795027; NCT01798251; NCT01815853; NCT01824459; NCT01843829; NCT01851941; NCT01870791; NCT01876927; NCT01880632; NCT01882933; NCT01889303; NCT01896531; NCT01913639; NCT01928290; NCT01928524; NCT01932580; NCT01935778; NCT01946061; NCT01962376; NCT01963702; NCT01980407); (2) in pancreatic cancer patients, near to invariably as part of the FOLFIRINOX (folinic acid plus 5-fluorouracil plus irinotecan plus oxaliplatin) regimen (NCT01760694; NCT01771146; NCT01811277; NCT01821612; NCT01821729; NCT01827553; NCT01835041; NCT01836432; NCT01867892; NCT01888978; NCT01896869; NCT01897454; NCT01905150; NCT01921751; NCT01926197; NCT01959139; NCT01964287); (3) in individuals affected by several other hematological and solid neoplasms, including extranodal natural killer (NK)/T-cell lymphoma (NCT01921790), breast carcinoma (NCT01937507), germ cell tumors (NCT01782339), HCC (NCT01775501), ICC (NCT01862315), gastrointestinal tumors (NCT01845337), malignancies of the biliary tract and gallbladder (NCT01811277; NCT01926236), and reproductive tract cancers (NCT01936974) ([Table 4](#T4){ref-type="table"}).

###### **Table 4.** Clinical trials recently launched to assess the therapeutic profile of oxaliplatin employed as off-label intervention.\*

  Indication(s)                                                       Phase                                                                   Status                                                              Note                                                                      Ref.
  ------------------------------------------------------------------- ----------------------------------------------------------------------- ------------------------------------------------------------------- ------------------------------------------------------------------------- -------------
  Biliary tract cancer                                                III                                                                     Not yet recruiting                                                  FOLFOX regimen                                                            NCT01926236
  Biliary tract cancer Pancreatic cancer                              II                                                                      Recruiting                                                          SOX regimen                                                               NCT01811277
  Breast carcinoma                                                    II                                                                      Recruiting                                                          FOLFOX regimen, administered to hepatic metastases by HAI                 NCT01937507
  Esophageal carcinoma Gastric carcinoma                              I                                                                       Recruiting                                                          DOS regimen                                                               NCT01928524
  II                                                                  Active, not recruiting                                                  XELOX regimen ± ginsenoside Rg3                                     NCT01757366                                                               
  Not yet recruiting                                                  XELOX regimen combined with radiotherapy ± carboplatin and paclitaxel   NCT01843829                                                                                                                                   
  FOLFIRINOX regimen ± trastuzumab                                    NCT01928290                                                                                                                                                                                                           
  SOL regimen                                                         NCT01980407                                                                                                                                                                                                           
  Recruiting                                                          EOX regimen combined with intravenous omega-3 fish oil                  NCT01870791                                                                                                                                   
  FLOT regimen                                                        NCT01932580                                                                                                                                                                                                           
  FOLFOX regimen ± aflibercept                                        NCT01747551                                                                                                                                                                                                           
  FOLFOX regimen combined with regorafenib                            NCT01913639                                                                                                                                                                                                           
  DOX regimen                                                         NCT01876927                                                                                                                                                                                                           
  FOLFOX regimen ± GDC-0068                                           NCT01896531                                                                                                                                                                                                           
  FOLFOX regimen combined radiation therapy                           NCT01889303                                                                                                                                                                                                           
  SOX regimen                                                         NCT01946061                                                                                                                                                                                                           
  XELOX regimen                                                       NCT01798251                                                                                                                                                                                                           
  XELOX regimen                                                       NCT01963702                                                                                                                                                                                                           
  XELOX regimen combined with radiotherapy and trastuzumab            NCT01748773                                                                                                                                                                                                           
  Completed                                                           FOLFOX regimen                                                          NCT01851941                                                                                                                                   
  II/III                                                              Not yet recruiting                                                      XELOX regimen                                                       NCT01880632                                                               
  Recruiting                                                          EOX regimen                                                             NCT01787539                                                                                                                                   
  III                                                                 Not yet recruiting                                                      DOX or XELOX regimen                                                NCT01935778                                                               
  SOX regimen                                                         NCT01824459                                                                                                                                                                                                           
  Recruiting                                                          Combined with gastrectomy and HIPEC                                     NCT01882933                                                                                                                                   
  FOLFOX or XELOX regimen                                             NCT01748851                                                                                                                                                                                                           
  SOX regimen                                                         NCT01761461                                                                                                                                                                                                           
  SOX regimen                                                         NCT01795027                                                                                                                                                                                                           
  XELOX regimen ± radiation therapy                                   NCT01815853                                                                                                                                                                                                           
  IV                                                                  Recruiting                                                              XELOX regimen ± bevacizumab                                         NCT01962376                                                               
  Gastrointestinal cancer                                             II                                                                      Not yet recruiting                                                  XELOX regimen or combined with teysuno                                    NCT01845337
  Germ cell tumors                                                    II                                                                      Recruiting                                                          Combined with conventional chemotherapeutics                              NCT01782339
  Hepatocellular carcinoma                                            II                                                                      Recruiting                                                          FOLFOX regimen combined with sorafenib                                    NCT01775501
  Intrahepatic cholangiocellular carcinoma                            II                                                                      Recruiting                                                          GEMOX regimen combined with HAI-based chemotherapy                        NCT01862315
  NK/T-cell lymphoma                                                  II                                                                      Recruiting                                                          GemAOD regimen combined with bevacizumab                                  NCT01921790
  Pancreatic cancer                                                   n.a.                                                                    Recruiting                                                          FOLFIRINOX regimen combined with IORT                                     NCT01760694
  FOLFIRINOX regimen                                                  NCT01771146                                                                                                                                                                                                           
  FOLFIRINOX regimen combined with chemoradiation and surgery         NCT01821612                                                                                                                                                                                                           
  I                                                                   Recruiting                                                              FOLFIRINOX regimen combined with 6,8-bis(benzylthio)octanoic acid   NCT01835041                                                               
  I/II                                                                Not yet recruiting                                                      FOLFIRINOX regimen ± PEGPH20                                        NCT01959139                                                               
  Recruiting                                                          FOLFIRINOX and GEMBRAX regimens combined                                NCT01964287                                                                                                                                   
  II                                                                  Enrolling by invitation                                                 FOLFIRINOX or GOFL regimen combined with chemoradiotherapy          NCT01867892                                                               
  Not yet recruiting                                                  FOLFIRINOX regimen                                                      NCT01896869                                                                                                                                   
  FOLFIRINOX regimen combined With 3D-CRT and capecitabine            NCT01921751                                                                                                                                                                                                           
  Sequential G-FLIP and G-FLIP-DM regimens combined with vitamin C    NCT01905150                                                                                                                                                                                                           
  Recruiting                                                          DOS or FOLFOX or GEMOX regimen                                          NCT01888978                                                                                                                                   
  FOLFIRINOX regimen combined with gemcitabine and IMRT               NCT01897454                                                                                                                                                                                                           
  FOLFIRINOX regimen combined with losartan and PBRT                  NCT01821729                                                                                                                                                                                                           
  III                                                                 Recruiting                                                              FOLFIRINOX regimen ± SBRT                                           NCT01926197                                                               
  FOLFIRINOX regimen combined with chemoradiation and immunotherapy   NCT01836432                                                                                                                                                                                                           
  FOLFIRINOX regimen combined with radiation therapy ± gemcitabine    NCT01827553                                                                                                                                                                                                           
  Reproductive tract tumors                                           II                                                                      Recruiting                                                          GEMOX regimen combined with platinum-based chemotherapy and bevacizumab   NCT01936974

**Abbreviations:** 3D-CRT, 3-dimensional conformal radiation therapy; 5-FU, 5 fluorouracil; DOS, docetaxel + oxaliplatin + S1; DOX, docetaxel + oxaliplatin + capecitabine; EOX, epirubicin + oxaliplatin + capecitabine; FLOT, 5-FU + oxaliplatin + docetaxel; FOLFIRINOX, folinic acid + 5-FU + irinotecan + oxaliplatin; FOLFOX, folinic acid + 5-FU + oxaliplatin; G-FLIP, gemcitabine + 5FU + folinic acid + irinotecan + oxaliplatin; G-FLIP-DM, G-FLIP + docetaxel + mitomycin C; GemAOD, gemcitabine + oxaliplatin + pegaspargase + dexamethasone; GEMBRAX, albumin-bound paclitaxel + gemcitabine; GEMOX, gemcitabine + oxaliplatin; GOFL, gemcitabine + oxaliplatin, folinic acid + 5-FU; HAI, hepatic arterial infusion; HIPEC, hyperthermic intraperitoneal chemoperfusion; IMRT, intensity-modulated radiation therapy; IORT, intraoperative radiation therapy; n.a., not available; NK, natural killer; PBRT, proton beam radiation therapy; PEGPH20, pegylated recombinant human hyaluronidase; SBRT, stereotactic body radiotherapy; SOL, S-1 + oxaliplatin + leucovorin; SOX, S-1 + oxaliplatin; XELOX, capecitabine + oxaliplatin. \*between 2012, December 1st and the day of submission.

Of note, during the last 13 mo no clinical trial has been initiated to evaluate the therapeutic profile of mitoxantrone in off-label oncological settings, and the status of only one of the studies discussed in our previous Trial Watches dealing with ICD inducers has changed since their publication.[@R124]^,^[@R125] Thus, official sources now list NCT01701375, testing mitoxantrone in combination with cytarabine and a cyclin-dependent kinase inhibitor (PD 0332991) in adults with relapsed and refractory acute leukemia or high-risk myelodysplastic syndrome, as terminated owing to sponsor withdrawal. Only 2 patients participated into this Phase I study, one of whom experienced relatively serious adverse effects including bone marrow aplasia and hyperbilirubinemia. Both these patients also suffered from less severe toxicities, including grade I-II mucositis (source <http://www.clinicaltrials.gov>).

Concluding Remarks
==================

It has now become clear that several clinically successful anticancer agents share the unsuspected ability to activate, rather than inhibit, the immune system.[@R10]^,^[@R11] The molecular and cellular circuitries that underlie such an immunostimulatory activity include ICD, a particular case of apoptosis that results in the activation of an adaptive immune response specific for dead cell-associated antigens.[@R35]^,^[@R36]^,^[@R43] Cyclophosphamide, doxorubicin, epirubicin, idarubicin, mitoxantrone, and oxaliplatin are all currently approved by the US FDA and other international regulatory agencies for the treatment of specific malignancies, and are all able to trigger ICD, as demonstrated by gold-standard vaccination experiments based on syngeneic tumor models.[@R35]^,^[@R36]^,^[@R43] Also patupilone belongs to the short list of bona fide ICD inducers,[@R8]^,^[@R9] but has not yet been approved for use in humans. Another epothilone, namely ixabepilone, is currently employed as a standalone therapeutic intervention in anthracycline-, taxane- and capecitabine-resistant breast carcinoma patients, or in combination with capecitabine for the treatment of anthracycline- and taxane-resistant locally advanced or metastatic breast carcinoma,[@R126]^,^[@R127] yet its ability to promote ICD remains unclear. As a matter of fact, the capacity of a given chemical to trigger the immunogenic demise of cancer cells cannot be anticipated by structural or functional considerations, as compounds that are as similar to each other as cisplatin and oxaliplatin have been shown to differ in this respect.[@R48]^,^[@R49] In line with this notion, although 7A7, a monoclonal antibody specific for murine EGFR, has been shown to trigger bona fide ICD,[@R128] whether clinically employed EGFR-targeting agents including panitumumab, cetuximab (2 monoclonal antibodies)[@R129]^,^[@R130] and erlotinib (a small compound that inhibits EGFR at the enzymatic level)[@R131]^,^[@R132] promote the immunogenic demise of cancer cells remains to be determined.

It is interesting to note that the abovementioned ICD inducers as well as many other currently employed anticancer agents that have an immunostimulatory activity have been identified and developed empirically, based on their ability to mediate relatively selective antineoplastic effects in vitro and in vivo, in immunodeficient mice implanted with human cancer cells.[@R10] Thus, the immunostimulatory potential of all these compounds has gone unnoticed for decades, in part owing to the experimental models employed until now (and still very diffuse), which were/are inapt to evaluate such a clinically relevant aspect of the pharmacology of a given agent. This also implies that many potentially efficient anticancer agents have never been fished out of large chemical libraries by standard screening procedures, or have gone lost at subsequent validation steps. We are deeply convinced that the development of preclinical models that do involve the immune system (for instance, syngeneic tumors developing in immunocompetent mice), or components thereof (for instance, cancer cells cultured in the presence of dendritic cells, macrophages, T cells, and/or NK cells),[@R10] coupled to a systematic analysis of the immunological parameters that may affect the clinical response of patients to therapy (immunomonitoring)[@R133]^,^[@R134] is crucial for the discovery of next-generation chemotherapeutics, i.e., molecules that simultaneously hit cancer cells while exerting potent immunostimulatory effects. We have already bumped into some of these compounds in the past century, it is now time to go actively get the missing ones.
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